Travere Therapeutics, Inc. (TVTX)
NASDAQ: TVTX · Real-Time Price · USD
52.13
+0.09 (0.16%)
Oct 9, 2026, 4:00 PM EDT - Market closed
Travere Therapeutics Stock Forecast
Stock Price Forecast
According to 15 analysts polled by S&P Global, Travere Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $75.21. The average 1-year stock price forecast is 44.29% higher than the current stock price, while the lowest is $62 (+18.94%) and the highest is $90 (+72.66%).
Price Target: $75.21 (+44.29%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Travere Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 12 | 12 | 12 | 12 | 12 | 12 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 15 | 15 | 15 | 15 | 15 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Buy Reiterates $89 | Buy | Reiterates | $89 | +70.74% | Oct 7, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $67 | Buy | Reiterates | $67 | +28.54% | Oct 2, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Maintains $71 | Buy | Maintains | $71 | +36.21% | Sep 24, 2026 |
| Wedbush | Wedbush | Buy Maintains $75 → $76 | Buy | Maintains | $75 → $76 | +45.80% | Sep 22, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $49 → $68 | Buy | Maintains | $49 → $68 | +30.46% | Aug 17, 2026 |
Financial Forecast
Revenue This Year
724.56M
from 490.73M
Increased by 47.65%
Revenue Next Year
1.08B
from 724.56M
Increased by 49.39%
EPS This Year
1.69
from 0.91
Increased by 86.16%
EPS Next Year
5.64
from 1.69
Increased by 232.85%
EPS and Forward PE are based on non-GAAP adjusted numbers.